KDR and colorectal carcinoma: RG is a multikinase inhibitor that targets a wide spectrum of kinases involved in angiogenesis and oncogenesis, such as VEGFR-2, platelet-derived growth factor receptor β (PDGFR-β), and the mitogen-activated protein kinases (MAPKs), and confers significant benefits in preventing CRC progression7,8.